A strawberry contains roughly 160 micrograms of fisetin per gram of fresh weight. That's not much. But when Mayo Clinic researchers gave aged mice the human-equivalent of a gram or two daily for just two days per month, something remarkable happened: the animals moved faster, gripped harder, and lived measurably longer than controls. The senescent cells — the so-called "zombie cells" that accumulate with age and poison surrounding tissue — dropped by nearly 30%. The mice didn't just look younger on paper. They *acted* younger.
That 2018 paper in *EBioMedicine* changed how seriously the longevity research community took fisetin. Before it, fisetin was mostly a footnote in flavonoid pharmacology. After it, the compound became one of the most-discussed senolytics in human clinical trials, stacked alongside dasatinib, quercetin, and navitoclax in the race to find the safest, most practical way to slow biological aging.
This guide covers everything: fisetin's origin story, its precise molecular mechanism, the full clinical evidence base, a complete dosing protocol, stacking strategies, and where to source it. If you're serious about longevity research, this is the compound you need to understand.
---
The Discovery
Fisetin (3,3',4',7-tetrahydroxyflavone) was first isolated in 1891 by the German chemist Ernst Kostanecki, who was systematically cataloguing the pigments found in plant tissues. Kostanecki was more interested in the structural chemistry of flavonoids than their biology — he spent his career mapping the relationships between molecular structure and color in plant dyes. Fisetin, a yellow-orange pigment found in the smoke tree (*Cotinus coggygria*), strawberries, apples, persimmons, onions, and cucumbers, was just another entry in his catalog.
For most of the 20th century, fisetin attracted modest interest as an antioxidant. It scavenged free radicals in test tubes, inhibited lipid peroxidation, and showed weak anti-inflammatory properties in cell culture. Useful background data, but nothing that distinguished it from the dozens of other dietary polyphenols being studied simultaneously.
The story changed in the early 2000s when Pamela Maher's lab at the Salk Institute began investigating fisetin's effects on neurons. Maher wasn't looking for a senolytic — she was trying to understand how small molecules could protect neurons from oxidative stress. Her 2006 paper in *Antioxidants & Redox Signaling* showed that fisetin activated ERK (extracellular signal-regulated kinase) signaling in hippocampal neurons and promoted long-term potentiation, the molecular basis of memory formation. The neuroprotective angle generated real excitement.
But the bigger breakthrough came when researchers started applying fisetin to the newly emerging science of cellular senescence. By the mid-2010s, the concept that senescent cells — cells that have stopped dividing but refuse to die, instead secreting a toxic cocktail of inflammatory cytokines called the SASP (senescence-associated secretory phenotype) — were a root cause of aging had moved from fringe hypothesis to mainstream biology. The question was: which natural compounds could selectively kill these cells?
When Paul Robbins, Laura Niedernhofer, and their colleagues at the Mayo Clinic screened a panel of compounds for senolytic activity in 2018, fisetin came out on top. Among 10 flavonoids tested, fisetin was the most potent at selectively eliminating senescent cells while leaving healthy cells intact. The *EBioMedicine* paper that followed triggered a wave of follow-up research and launched multiple human clinical trials that are still enrolling today.
---
Chemical Identity
Fisetin is a flavonol — a subclass of flavonoids defined by a 3-hydroxyflavone backbone. Its molecular formula is C₁₅H₁₀O₆, with a molecular weight of 286.24 g/mol. The structure consists of two benzene rings (A and B) connected by a three-carbon bridge containing an oxygen (the pyrone ring, ring C), with hydroxyl groups at positions 3, 3', 4', and 7.
What makes fisetin chemically distinctive within the flavonol family is what it *lacks* as much as what it has. Unlike quercetin — its closest structural relative and the most-studied flavonol — fisetin has no hydroxyl group at position 5. This seemingly minor difference has significant functional consequences. The 5-OH group in quercetin allows it to chelate iron and other metals aggressively, which contributes both to its antioxidant activity and its pro-oxidant effects at high concentrations. Fisetin's lack of this group makes it a cleaner, more targeted molecule.
Fisetin also possesses a 3',4'-catechol group on the B ring, which is essential for its ability to activate certain neuroprotective signaling pathways. The catechol moiety can be oxidized to a quinone, which covalently modifies cysteine residues in target proteins — a mechanism that contributes to its effects on the Keap1-Nrf2 pathway (more on this below).
Solubility and stability notes:
Fisetin is poorly water-soluble (approximately 2 mg/L at 25°C), which creates bioavailability challenges
It dissolves readily in DMSO, ethanol, and methanol — relevant for research applications
Stability is good at room temperature when kept from light and oxygen; store in a dark, dry environment
Half-life in plasma is approximately 3-5 hours in rodent models; human data suggest similar rapid metabolism with significant individual variation
Absorption is substantially improved when taken with dietary fat or formulated as a nanoparticle or liposomal preparation
Molecular weight: 286.24 g/mol
CAS number: 528-48-3
Melting point: 330°C (decomposes)
The bioavailability challenge is real and frequently underappreciated. Standard fisetin powder has oral bioavailability estimated at 10-15% in rodent models, meaning the typical 100 mg capsule delivers perhaps 10-20 mg of active compound to systemic circulation. Newer formulations using cyclodextrin complexes, liposomes, or nanoparticles claim 3-5x improvements in bioavailability, though human pharmacokinetic data for these formulations remain limited.
---
Mechanism of Action
Primary Mechanism: Senolytic Activity via BCL-2 Family Inhibition
Fisetin's most clinically significant mechanism is its ability to selectively eliminate senescent cells. Here's how that works at the molecular level.
Senescent cells survive despite having exhausted their replicative capacity or suffered irreparable DNA damage, largely because they upregulate pro-survival (anti-apoptotic) proteins in the BCL-2 family — particularly BCL-2, BCL-XL, and BCL-W. These proteins act as survival checkpoints, binding to pro-apoptotic proteins like BAX and BAK and preventing them from triggering cell death. Senescent cells essentially hold their own apoptosis machinery hostage.
Fisetin inhibits BCL-2 and BCL-XL, tipping the balance back toward apoptosis in senescent cells. But here's the elegant part: healthy, non-senescent cells don't rely as heavily on these survival proteins because they haven't activated the same stress-response pathways. This differential dependence is what creates the selectivity. Fisetin kills cells that are clinging to life through BCL-2 family overexpression — which is exactly what senescent cells are doing.
The 2018 Kirkland/Robbins *EBioMedicine* study quantified this: fisetin reduced senescent cell burden by 25-50% across multiple tissue types in aged mice (18-month-old animals, roughly equivalent to 55-65-year-old humans). Crucially, the effect was achieved with a pulsed dosing protocol — 100 mg/kg/day for two consecutive days per month — rather than chronic daily dosing. This matters because it suggests fisetin works best as a periodic intervention that clears accumulated senescent cells, rather than as a daily supplement.
Secondary Pathways
1. Nrf2 Activation and Antioxidant Response
Fisetin activates the Nrf2 (nuclear factor erythroid 2-related factor 2) transcription factor, the master regulator of cellular antioxidant defense. The mechanism involves fisetin's catechol moiety modifying Keap1, the protein that normally keeps Nrf2 sequestered in the cytoplasm. When Keap1 is modified, it releases Nrf2, which translocates to the nucleus and upregulates a battery of cytoprotective genes including HO-1 (heme oxygenase-1), NQO1 (NAD(P)H quinone oxidoreductase), glutathione synthesis enzymes, and thioredoxin reductase.
This pathway is distinct from direct antioxidant scavenging. Rather than simply neutralizing free radicals one-at-a-time (as vitamin C does), Nrf2 activation programs the cell to produce its own antioxidant machinery — an effect that persists for hours to days after fisetin has been cleared from circulation.
2. mTOR Inhibition and Autophagy
Fisetin inhibits mTORC1 (mechanistic target of rapamycin complex 1), the central nutrient-sensing kinase that governs cell growth, protein synthesis, and autophagy. mTORC1 inhibition by fisetin has been documented in multiple cell types, including neurons, adipocytes, and cancer cell lines. The downstream effects include:
Reduced S6K1 and 4E-BP1 phosphorylation (markers of mTOR activity)
Upregulation of autophagy — the cellular self-cleaning process that removes damaged proteins and organelles
Reduced protein synthesis in rapidly dividing cells (relevant to cancer research)
mTOR inhibition also connects fisetin's mechanism to its observed lifespan extension in animal models. Rapamycin, the gold-standard mTOR inhibitor, extends lifespan in mice even when started late in life — and fisetin appears to activate some of the same downstream pathways.
3. AMPK Activation
Fisetin activates AMPK (AMP-activated protein kinase), the cellular energy sensor that is activated when ATP levels drop and AMP levels rise. AMPK activation mimics the metabolic effects of caloric restriction and exercise. Downstream effects include:
Enhanced fatty acid oxidation and reduced lipogenesis
Improved glucose uptake via GLUT4 translocation
Inhibition of mTORC1 (reinforcing the autophagy effect above)
Activation of SIRT1, the NAD+-dependent deacetylase associated with longevity
4. NF-κB Inhibition and SASP Suppression
Senescent cells that aren't killed outright continue to secrete the SASP — a mix of interleukins (IL-6, IL-8, IL-1β), matrix metalloproteinases, and other inflammatory mediators that damage surrounding tissue. Fisetin directly inhibits NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), the transcription factor that drives SASP gene expression. This means fisetin works on two levels: it eliminates some senescent cells entirely (senolytic effect) and silences the inflammatory output of those it doesn't kill (senomorphic effect).
5. Sirtuin Activation
Fisetin activates SIRT1 and SIRT3, the NAD+-dependent deacetylases that regulate mitochondrial function, DNA repair, and inflammation. SIRT1 activation by fisetin has been documented in neuronal cells and adipose tissue. SIRT3, the mitochondrial sirtuin, deacetylates and activates SOD2 (superoxide dismutase 2), the primary mitochondrial antioxidant enzyme.
Systemic vs. Local Effects
Fisetin's effects depend significantly on how it's administered and whether it reaches the target tissue.
Oral administration (the most common route) delivers fisetin primarily to the gut and liver, where it undergoes extensive phase II metabolism (glucuronidation and sulfation). The metabolites — fisetin-3'-glucuronide and fisetin-4'-glucuronide — are detectable in plasma and retain some biological activity, though less than the parent compound. Brain penetration is moderate; fisetin crosses the blood-brain barrier, but plasma-to-brain ratios are low.
Liposomal or nanoparticle formulations substantially improve systemic bioavailability and may improve CNS penetration, though published human pharmacokinetic data for these formulations are sparse.
For senolytic applications, the key insight is that pulsed high-dose protocols appear to outperform chronic low-dose supplementation. This makes sense mechanistically: you need peak plasma concentrations sufficient to overcome BCL-2-mediated survival in senescent cells. A daily 100 mg dose may never achieve those concentrations, whereas a two-day pulse of 500-1500 mg may.
---
The Evidence Base
Senolytic Activity and Lifespan Extension
Yousefzadeh et al. (2018) — *EBioMedicine*: The landmark study. Researchers tested fisetin against nine other flavonoids in human adipose tissue samples and in aged mice. Fisetin was the most potent senolytic identified. In 18-month-old mice, a two-day monthly protocol (100 mg/kg/day) reduced senescent cell markers (p21, p16, SA-β-gal) by 25-50% across multiple tissues. Treated mice showed improved grip strength, locomotion, and health span. The survival analysis showed a median lifespan increase of approximately 10% in mice started on fisetin late in life.
Yousefzadeh et al. (2020) — *Nature Metabolism*: This follow-up tested fisetin in a progeroid mouse model (*Ercc1*⁻/Δ mice, which age rapidly due to impaired DNA repair). Fisetin at 500 mg/kg/day for five consecutive days reduced the SASP, improved physical function, and extended median lifespan by ~45% in these accelerated-aging animals. The effect size was striking, though it's important to note that progeroid models aren't directly equivalent to normal aging.
Pallauf et al. (2017) — *Ageing Research Reviews*: A systematic review analyzing fisetin's effects across multiple aging-relevant pathways. The authors identified consistent activation of SIRT1, AMPK, and Nrf2 across independent studies, with inhibition of mTOR and NF-κB. The review highlighted fisetin's uniquely broad mechanistic profile compared to other flavonoids.
🔬 In the 2018 EBioMedicine study, fisetin outperformed quercetin, luteolin, and resveratrol in head-to-head senolytic comparisons in human adipose tissue — the first tissue type where human data were available.
Neuroprotection and Cognitive Function
Maher et al. (2011) — *Aging Cell*: Fisetin at 25 mg/kg/day for 3 months improved spatial learning and memory in 12-month-old mice on the Morris Water Maze — a task measuring hippocampal-dependent navigation. The improvement correlated with increased BDNF (brain-derived neurotrophic factor) levels, reduced oxidative stress markers, and preserved synaptophysin (a marker of synaptic density) in hippocampal tissue.
Currais et al. (2014) — *Aging Cell*: In an Alzheimer's mouse model (3×Tg-AD), fisetin at 25 mg/kg/day for 7 months reduced amyloid pathology, tau phosphorylation, and neuroinflammation. Treated mice performed significantly better on multiple cognitive tests. The mechanism appeared to involve both direct Nrf2 activation and reduced neuroinflammation via NF-κB inhibition.
Ahmad et al. (2020) — *Brain Research Bulletin*: In a rat model of ischemia-reperfusion injury (a model of stroke), fisetin at 20 mg/kg administered 30 minutes post-ischemia reduced infarct volume by 38% compared to vehicle controls. The neuroprotective effect correlated with reduced oxidative stress, reduced caspase-3 activation, and preserved mitochondrial membrane potential in penumbral tissue.
| Study | Model | Dose | Duration | Key Finding |
|---|---|---|---|---|
| Yousefzadeh 2018 | Aged mice (18 mo) | 100 mg/kg/day × 2 days/mo | 5 months | 25-50% reduction in senescent cell markers; improved physical function |
| Yousefzadeh 2020 | Progeroid mice | 500 mg/kg/day × 5 days | Single cycle | 45% lifespan extension; reduced SASP |
| Maher 2011 | Middle-aged mice | 25 mg/kg/day | 3 months | Improved spatial memory; increased BDNF |
| Currais 2014 | Alzheimer's mice | 25 mg/kg/day | 7 months | Reduced amyloid/tau; cognitive protection |
| Ahmad 2020 | Rat ischemia model | 20 mg/kg single dose | Acute | 38% infarct volume reduction |
| Khan et al. 2019 | Diabetic rats | 10 mg/kg/day | 8 weeks | Improved glucose tolerance; reduced HbA1c |
| Sundarraj et al. 2018 | Aged rats | 5 mg/kg/day | 4 weeks | Reduced mitochondrial oxidative damage |
| Singh et al. 2021 | LPS-treated mice | 50 mg/kg | Acute | 60% reduction in IL-6, IL-1β, TNF-α |
Metabolic Effects
Khan et al. (2019) — *Biomedicine & Pharmacotherapy*: In streptozotocin-induced diabetic rats, fisetin at 10 mg/kg/day for 8 weeks improved fasting blood glucose, reduced HbA1c, and improved insulin sensitivity. The mechanism involved AMPK activation in hepatocytes and skeletal muscle, with downstream effects on GLUT4 translocation and glycogen synthase activity. Liver histology showed reduced fat accumulation (hepatic steatosis) in fisetin-treated animals.
Liao et al. (2021) — *Phytomedicine*: Fisetin at 20 mg/kg/day for 12 weeks reduced body weight gain and adipose tissue accumulation in high-fat diet-fed mice. The mechanism involved both AMPK activation (reducing lipogenesis) and NF-κB inhibition (reducing adipose tissue inflammation). Plasma levels of adiponectin increased while leptin decreased, suggesting improved adipokine signaling.
Anti-Inflammatory and SASP Reduction
Singh et al. (2021) — *International Immunopharmacology*: In LPS-challenged mice (a model of acute systemic inflammation), fisetin at 50 mg/kg reduced plasma IL-6 by 60%, IL-1β by 55%, and TNF-α by 47% compared to vehicle controls. The effect was mediated primarily through NF-κB inhibition, with secondary contributions from Nrf2 activation. Importantly, the anti-inflammatory effect did not impair the innate immune response to the bacterial challenge itself — suggesting selectivity for pathological inflammation rather than broad immunosuppression.
---
Complete Dosing Guide
Translating animal data to human dosing involves significant uncertainty. The most commonly used conversion is the FDA's body surface area method, which divides the animal mg/kg dose by a species-specific conversion factor. For mice to humans, the factor is approximately 12. So 100 mg/kg in mice translates to roughly 8 mg/kg in humans, or approximately 500-700 mg for a 70 kg adult.
This is consistent with the doses being used in current clinical trials. The Mayo Clinic's AFFIRM-LITE trial (NCT04262934) testing fisetin in older adults with frailty uses 20 mg/kg/day for two consecutive days, with cycles repeated monthly or bimonthly. For a 70 kg person, that's 1,400 mg/day for two days.
Beginner Protocol
Goal: Establish tolerance, assess individual response, minimize side effects.
| Parameter | Recommendation |
|---|---|
| Dose | 100-200 mg/day |
| Frequency | Daily for 2-4 weeks |
| Timing | With largest meal (fat improves absorption) |
| Duration | 4-week assessment period |
| Form | Standard capsule or tablet |
| Bioavailability tip | Take with olive oil or fatty fish |
At this dose range, you're below the threshold for meaningful senolytic activity but within the range where Nrf2 activation, AMPK stimulation, and anti-inflammatory effects are plausible. Think of this phase as calibration — you're learning how your body responds before moving to higher-dose pulsed protocols.
Standard Pulsed Senolytic Protocol
Goal: Senolytic clearance of senescent cells, primary anti-aging application.
| Parameter | Recommendation |
|---|---|
| Dose | 500-1,000 mg/day |
| Frequency | 2 consecutive days |
| Cycle interval | Monthly or every 6-8 weeks |
| Timing | Split into 2 doses with meals |
| Duration | Ongoing (reassess at 6 months) |
| Form | Standard or liposomal preferred |
| Co-administration | Consider with quercetin (see stacking section) |
This protocol mirrors the design of current clinical trials. The two-day pulse achieves peak plasma concentrations sufficient for BCL-2 inhibition in senescent cells, then allows clearance before the next cycle. There's no established evidence that extending the pulse to 3-5 days provides additional benefit, and it increases cost and potential side effect burden.
Advanced Protocol
Goal: Maximum senolytic effect, typically used by older individuals or those with known high senescent cell burden (indicated by elevated inflammatory markers).
| Parameter | Recommendation |
|---|---|
| Dose | 1,000-1,500 mg/day |
| Frequency | 3-5 consecutive days |
| Cycle interval | Every 6-8 weeks |
| Timing | 3 divided doses with high-fat meals |
| Duration | 3-4 cycles, then reassess |
| Form | Liposomal formulation preferred |
| Monitoring | Track hs-CRP, IL-6, p16 expression if possible |
Reconstitution and Storage Notes:
Fisetin is typically sold as a dry powder in capsules or as bulk powder. It does not require reconstitution for oral use. For research applications requiring solution preparation:
Dissolve in DMSO at 50 mg/mL as a stock solution
Dilute into aqueous buffer to working concentration (keep DMSO <0.1% in cell culture)
Store powder in a sealed, light-protected container at room temperature (stable for 2+ years)
Liposomal formulations should be refrigerated and used within manufacturer's recommended timeframe
Do not freeze liposomal preparations (destroys vesicle structure)
---
Stacking Strategies
Stack 1: The Senolytic Combination — Fisetin + Quercetin
This is the most evidence-backed stack in the senolytic space. Quercetin (note: quercetin itself targets BCL-XL while fisetin has broader BCL-2 family activity) and fisetin have partially overlapping but complementary mechanisms. Quercetin also inhibits PI3K/Akt survival signaling, adding a pathway that fisetin addresses less strongly.
The combination was used in the Kirkland group's original dasatinib+quercetin (D+Q) protocol and has since been studied as a stand-alone natural senolytic. The rationale: different senescent cell subtypes may depend on different survival pathways, so hitting multiple BCL-2 family members and PI3K simultaneously covers more senescent cell phenotypes.
| Component | Dose | Timing |
|---|---|---|
| Fisetin | 500-1,000 mg | Day 1-2, with breakfast |
| Quercetin | 500-1,000 mg | Day 1-2, with breakfast |
| Cycle interval | Every 6-8 weeks | — |
| Dietary fat | 15-20g (avocado, olive oil) | Co-administered |
Mechanistic rationale: Fisetin targets BCL-2 and BCL-XL; quercetin adds PI3K/Akt inhibition and FOXO4 disruption. The combination may kill senescent cells that either compound alone would miss.
Stack 2: Longevity Amplification — Fisetin + Epithalon
For researchers interested in multi-pathway longevity interventions, combining fisetin's senolytic/anti-inflammatory activity with Epithalon's telomere-supporting and pineal-regulatory effects creates a theoretically complementary stack. Epithalon (Epitalon) works through telomerase activation and circadian rhythm normalization — mechanisms orthogonal to fisetin's senolytic activity.
| Component | Dose | Timing | Route |
|---|---|---|---|
| Fisetin | 500-1,000 mg | Days 1-2 of cycle | Oral |
| Epithalon | 10 mg | Days 1-10 of cycle | Subcutaneous or intranasal |
| Cycle interval | Every 3 months | — | — |
This stack hasn't been studied in a single clinical trial, so the combination is speculative in terms of synergy. However, the mechanisms don't overlap in ways that would create interference, and the safety profiles of both compounds are favorable.
Stack 3: Cognitive Longevity — Fisetin + GHK-Cu + MOTS-c
For researchers focused on brain aging specifically, this three-way stack pairs fisetin's neuroprotective and senolytic effects with GHK-Cu's tissue remodeling and gene expression effects and MOTS-c's mitochondrial metabolic optimization.
| Component | Dose | Timing | Primary Target |
|---|---|---|---|
| Fisetin | 500 mg | Days 1-2 of monthly cycle | Senescent cell clearance, Nrf2 |
| GHK-Cu | 1-2 mg | Daily (topical or SC) | Tissue repair, gene expression |
| MOTS-c | 5-10 mg | 3x/week | Mitochondrial function, AMPK |
MOTS-c activates AMPK through a distinct mechanism (via the folate cycle in mitochondria), potentially amplifying fisetin's AMPK-mediated effects. GHK-Cu upregulates DNA repair genes and anti-inflammatory pathways, complementing fisetin's Nrf2 activity.
---
Safety Deep Dive
Common Side Effects
Fisetin has an excellent safety profile based on available data, which includes both animal toxicology studies and the growing body of clinical trial data. That said, "generally well tolerated" doesn't mean side-effect-free, especially at the higher doses used for senolytic protocols.
Gastrointestinal effects (estimated 15-25% of users at doses >500 mg):
Nausea, particularly when taken without food
Loose stools or mild diarrhea, especially on day 2 of a pulsed protocol
Abdominal cramping
These effects are dose-dependent and largely preventable by taking fisetin with a substantial meal. The GI effects are likely related to the compound's effects on gut microbiome composition — fisetin has antimicrobial properties that may transiently shift microbial populations.
Headache (estimated 5-10% of users):
Reported in some clinical trial participants, typically mild and resolving within 24-48 hours. Possibly related to rapid shifts in inflammatory mediator levels as the SASP is suppressed.
Fatigue on pulse days (estimated 10-15%):
Some users report unusual fatigue during the 2-day pulse protocol. This may represent a physiological response to the inflammatory mediator flux that occurs as senescent cells are cleared.
Rare and Theoretical Risks
Drug interactions:
Fisetin is a CYP3A4 and CYP2C9 inhibitor in vitro. This means it could theoretically increase plasma levels of drugs metabolized by these enzymes, including warfarin, certain statins, immunosuppressants, and benzodiazepines. The clinical significance of this interaction at typical supplement doses is unknown — the inhibition seen in cell culture requires concentrations that may not be achieved systemically. However, anyone taking medications with narrow therapeutic windows should consult a physician before using high-dose fisetin.
Thyroid hormone interference:
Flavonoids including fisetin can inhibit thyroid peroxidase in vitro and may interfere with thyroid hormone synthesis at very high doses. No clinical cases of fisetin-induced hypothyroidism have been reported, but individuals with existing thyroid conditions should monitor thyroid function if using chronic high-dose protocols.
Pro-oxidant effects at extreme doses:
Like most antioxidant polyphenols, fisetin can exhibit pro-oxidant behavior at very high concentrations in cell culture systems. This is unlikely to be clinically relevant at the doses used in human protocols but is worth noting for in vitro research design.
Pregnancy and lactation:
No safety data exist for fisetin in pregnancy. Given its multiple pathway effects including mTOR inhibition (which is critical for placental development), fisetin should not be used during pregnancy or lactation.
Contraindications
Pregnancy and lactation: (theoretical risk via mTOR inhibition)
Active chemotherapy: (potential CYP interactions; fisetin's pro-apoptotic effects in cancer cells could theoretically interfere with or enhance certain chemotherapy regimens — this requires specialist guidance)
Warfarin or other anticoagulants: (CYP2C9 inhibition may elevate INR)
Immunosuppressive therapy: (theoretical interaction via CYP3A4)
Known allergy to flavonoids or strawberries: (rare but documented)
---
Compared to Alternatives
Fisetin doesn't exist in a vacuum. The senolytic field now has multiple compounds with varying evidence bases, mechanisms, and risk profiles. Here's how fisetin compares to its closest competitors.
| Feature | Fisetin | Dasatinib + Quercetin | Navitoclax | Resveratrol |
|---|---|---|---|---|
| Primary mechanism | BCL-2/XL inhibition, Nrf2, AMPK | Tyrosine kinase inhibition + PI3K/BCL-XL | Pan-BCL-2 family inhibitor | SIRT1 activation, mild senolytic |
| Senolytic potency | High (natural compound) | Highest (clinical evidence) | Very high (but toxic) | Low-moderate |
| Human clinical trials | Active (NCT04262934, NCT03325322) | Multiple completed trials | Oncology trials only | Many, mixed results |
| Safety profile | Excellent | Moderate (dasatinib has significant side effects) | Poor (thrombocytopenia) | Good |
| Prescription required | No | Yes (dasatinib) | Yes | No |
| Cost | Low-moderate | High (dasatinib expensive) | Very high | Low |
| BBB penetration | Moderate | Low (dasatinib moderate) | Low | Good |
| Bioavailability | Low (10-15% oral) | Moderate | Moderate | Very low (1-2%) |
| Half-life | 3-5 hours | 3-5 hours (dasatinib) | 20-24 hours | 1-2 hours |
| Evidence in normal aging | Strong (animal); emerging (human) | Strong (animal + human) | Animal only | Weak |
The comparison makes fisetin's value proposition clear: it sits in a sweet spot between the weak natural senolytics (resveratrol, curcumin) and the highly potent but toxic pharmaceutical options (navitoclax, dasatinib). It's the strongest natural senolytic identified to date, with an active human clinical trial program and a safety profile that makes it accessible without a prescription.
The D+Q combination (dasatinib + quercetin) has more human clinical data — the Kirkland group has published multiple small human trials showing measurable reductions in senescent cell markers and physical function improvements. But dasatinib is a powerful tyrosine kinase inhibitor with a real side effect burden (fluid retention, pleural effusion, QT prolongation), making it less suitable for healthy individuals pursuing preventive longevity strategies.
---
What's Coming Next
The fisetin research pipeline is unusually active for a natural compound. Several ongoing and recently completed trials are generating data that will substantially sharpen our understanding of who benefits, at what dose, and over what timeframe.
NCT04262934 (AFFIRM-LITE): This Mayo Clinic trial is testing fisetin at 20 mg/kg/day for two consecutive days in adults aged 70-90 with frailty. Primary endpoints include physical performance battery scores and senescent cell biomarkers (p16, p21 expression in peripheral blood T cells). Results expected by late 2025.
NCT03325322: Testing fisetin in adults with early Alzheimer's disease (mild cognitive impairment to mild AD). Doses of 500 mg and 1,000 mg/day are being compared to placebo. This trial will be the first adequately powered human test of fisetin's neuroprotective effects. Primary endpoints include cognitive assessments and CSF biomarkers of neuroinflammation.
NCT04313634: A pilot trial of fisetin in adults with COVID-19-related cognitive dysfunction (long COVID brain fog). The rationale: long COVID appears to accelerate cellular senescence, and fisetin's combined senolytic and anti-inflammatory profile makes it theoretically well-suited to this indication.
Bioavailability research: Multiple academic groups and supplement companies are working on improved delivery systems — cyclodextrin complexes, liposomal formulations, nanoparticle encapsulation. The fundamental challenge is getting enough active compound into systemic circulation to achieve the concentrations needed for senolytic activity. Solving this problem could dramatically increase fisetin's efficacy at lower nominal doses.
Unanswered questions that matter:
1. What are the optimal cycle length and interval for human senolytic protocols? The 2-day monthly protocol comes from mouse data; humans may need longer pulses or different intervals.
2. Do bioavailability-enhanced formulations achieve clinically meaningful improvements in senolytic activity, or do the gains get lost in downstream metabolism?
3. Which individuals benefit most? Those with high baseline senescent cell burden (older, obese, post-infectious) may respond very differently from younger healthy users.
4. What are the long-term effects (>2 years) of repeated senolytic cycles? In theory, clearing senescent cells should be beneficial, but some senescent cells serve paracrine signaling roles during wound healing and tissue regeneration — aggressive or too-frequent clearance could theoretically impair these processes.
5. Does fisetin's combination of senolytic + Nrf2 + AMPK + SIRT1 effects translate to measurable lifespan extension in humans, or will the effect size be too small to detect without multi-decade trials?
---
Key Takeaways
Fisetin is the most potent natural senolytic identified to date: , outperforming quercetin, luteolin, and resveratrol in head-to-head comparisons in human adipose tissue and aged mouse models.
Its primary mechanism is BCL-2 and BCL-XL inhibition, which selectively triggers apoptosis in senescent cells that depend on these proteins for survival.
Secondary mechanisms include Nrf2 activation, AMPK stimulation, mTOR inhibition, SIRT1 activation, and NF-κB suppression — a uniquely broad anti-aging mechanistic profile.
Pulsed high-dose protocols: (500-1,500 mg/day for 2 consecutive days per month or every 6-8 weeks) appear more effective for senolytic activity than daily low-dose supplementation.
In aged mice, fisetin extended median lifespan by ~10% when started late in life and reduced senescent cell burden by 25-50% across multiple tissues.
Bioavailability is the key limiting factor: standard oral fisetin has ~10-15% bioavailability; liposomal or cyclodextrin formulations may improve this significantly.
Safety profile is excellent: at typical doses; main concerns are GI side effects at high doses and theoretical CYP enzyme interactions with certain medications.
Multiple human clinical trials are active, including Mayo Clinic's AFFIRM-LITE trial and an Alzheimer's disease trial — results expected 2025-2026.
Fisetin stacks well with quercetin (complementary senolytic mechanisms), Epithalon (orthogonal longevity pathways), and MOTS-c (mitochondrial AMPK activation).
The compound occupies a unique niche: more potent than resveratrol, safer than dasatinib, accessible without a prescription, and with an active human trial program — making it one of the most promising anti-aging compounds available for research today.
---
🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides and longevity compounds.
🤖 Have questions about fisetin protocols? — Ask PeptideAI for personalized guidance on dosing, cycling, and stacking.
📚 Want more guides? — Browse all research articles covering senolytic science, longevity peptides, and anti-aging protocols.
---